title: Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
abstract: OBJECTIVE
  To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% dosed once daily for the treatment of ocular inflammation and pain following cataract extraction with posterior chamber intraocular lens implantation.
  
  
  METHODS
  A total of 455 subjects (455 study eyes: 230 bromfenac, 225 placebo) were enrolled in two randomized double-masked, placebo-controlled, clinical trials at 64 ophthalmology clinics in the United States. Subjects were randomized to receive either bromfenac 0.09% or placebo dosed once daily. Dosing began 1 day before cataract surgery (Day -1), continued on day of surgery (Day 0), and for 14 days following surgery. Evaluations were completed on Days 1, 3, 8, 15 and 22. The primary efficacy endpoint was cleared summed ocular inflammation score (SOIS) by Day 15. The secondary efficacy endpoint was the number of subjects who were pain-free at Day 1.
  
  
  RESULTS
  The bromfenac 0.09% group was significantly higher compared to the placebo group in the primary endpoint of the proportion of subjects who had cleared ocular inflammation by Day 15 (P < 0.0001). The mean SOIS for the bromfenac 0.09% group was lower than the placebo group at Days 3, 8, 15, and 22 (P < 0.0001). More bromfenac 0.09% subjects were pain free at Days 1, 3, 8, and 15 (P < 0.0001). Fewer subjects in the bromfenac 0.09% group withdrew from the clinical trials due to lack of efficacy at Day 15 (P < 0.0001). Fewer adverse events were reported in the bromfenac 0.09% group than the placebo group. Limitations included advanced age, female predominance, and surgical nuances among cataract surgeons, making cross-trial comparisons difficult.
  
  
  CONCLUSIONS
  Bromfenac ophthalmic solution 0.09% dosed once daily is clinically safe and effective for the treatment of ocular inflammation and the reduction of ocular pain associated with cataract surgery.
authors.affiliation: Silverstein Eye Centers, Kansas City, MO, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Silverstein
authors.forename: Melissa G
authors.initials: MG
authors.lastname: Cable
authors.forename: Ehsan
authors.initials: E
authors.lastname: Sadri
authors.forename: James H
authors.initials: JH
authors.lastname: Peace
authors.forename: Raymond
authors.initials: R
authors.lastname: Fong
authors.forename: Simon P
authors.initials: SP
authors.lastname: Chandler
authors.forename: James A
authors.initials: JA
authors.lastname: Gow
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Klier
authors.forename: Timothy R
authors.initials: TR
authors.lastname: McNamara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D001577:Benzophenones / Q000008:administration & dosage* / Q000009:adverse effects; D001969:Bromobenzenes / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D009994:Osmolar Concentration; D010149:Postoperative Pain / Q000188:drug therapy*; D010919:Placebos; D011183:Postoperative Complications / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; D009883:Ophthalmic Solutions; D010919:Placebos; C053083:bromfenac